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g.2012.0Abstract The relationship between increased homocysteine (Hcy) level and epileptic seizure
remains controversial in human, despite a growing evidence of the pro-convulsive effect of the hype-
rhomocysteinemia (HHcy) observed in the animal studies. The mechanism of this association with
epileptogenesis has not been clearly understood, although there is emerging evidence to support the
unfavorable effects of some anti-epileptic drugs (AEDs) on the plasma homocysteine (Hcy) concen-
trations. The aim of this study was to uncover the relationship between the levels of homocysteine
(Hcy), the cofactors involved in its metabolism as folic acid and vitamin B12 and anti-epileptic
drugs (AEDs) in epileptic patients. Serum level of homocysteine (Hcy), folic acid and vitamin
B12 was measured in 60 patients with idiopathic epilepsy; and its level was compared to 30 healthy
children serving as control group. No signiﬁcant difference was found regarding the plasma homo-
cysteine (Hcy) levels between patients (both receiving anti-epileptics and non anti-epileptic drug
users) and controls. Epileptic patients on polytherapy showed higher mean serum levels of homo-
cysteine (Hcy) and lower mean serum levels of folic acid compared to those on monotherapy. How-
ever, the mean serum levels of homocysteine (Hcy), vitamin B12 and folic acid showed non
signiﬁcant differences between patients using valproic acid (VPA) or carbamazepine (CBZ). Dura-
tion of AED therapy showed a signiﬁcant positive correlation with mean serum levels of homocys-
teine (Hcy) and a signiﬁcant negative correlation with mean serum levels of folic acid. To conclude;ildren’s Hospital, Faculty of
bassia, Cairo 11566, Egypt.
(R.H. Shatla).
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Homocysteine (Hcy), is a sulfur-containing amino acid that is
formed by de-methylation of methionine [1]. Plasma Hcy con-
centrations vary with ethnic background, increase with age, are
higher in adult men and postmenopausal women, and lowest
in children [2]. In children, hyperhomocysteinemia (HHcy) is
deﬁned according to age and (after puberty) sex-speciﬁc per-
centiles [3].
Folic acid and vitamin B12 have roles in the metabolism of
Hcy and defects in the metabolism of any of them may lead to
increased serum Hcy levels, resulting in atherosclerosis [4,5].
It has been reported that Hcy induces neuronal cell death
by stimulating N-methyl D aspartate (NMDA) receptors
mediating excitotoxicity, as well as by producing free radicals
[6] and induction of apoptosis [7]. Its metabolites, homocysteic
acid and L-Hcy sulﬁnic acid, also exhibit high excitotoxic po-
tency by interacting with different glutamate receptor subtypes
[8]. They are potent agonists of the NMDA-type glutamate
receptor, which are linked with epileptogenesis [9].
Also, stimulation of NMDA receptors by Hcy with exces-
sive calcium inﬂux causes reactive oxygen generation and
neurotoxicity that contribute to the cognitive changes and
the marked increased risk of cerebrovascular disease in chil-
dren and young adults with homocysteinuria. In addition, dis-
ruption of blood–brain barrier (BBB) in patients with stroke
and HHcy exposes the brain to near plasma levels of Hcy
and increases neurotoxicity [6].
In animals, systemic administration of high doses of Hcy
produces convulsive seizures, a fact that has been exploited
in models of experimental epilepsy [10]. Furthermore, there
are some data from animal studies demonstrating that Hcy
sequesters adenosine, an endogenous anticonvulsant, and
thereby reduces the seizure threshold [11].
Therefore, Hcy through these mechanisms, may reduce sei-
zure threshold and increase seizure frequency in patients trea-
ted with AEDs. Other mechanisms, such as oxidative stress,
DNA damage, inhibition of NA/K-ATPase and activation of
caspases, could be involved in Hcy-induced neuronal excito-
toxicity [12].
There is little information on the inﬂuence of antiepileptic
drugs on Hcy levels in pediatric patients. HHcy was reported
in 15.5% of children receiving AEDs [13]. Little is known on
how phenytoin (PHT), valproic acid (VPA) and carbamaze-
pine (CBZ) exert their effect on Hcy metabolism. It has been
suggested that enzyme inducers, can directly modulate the
activity of different liver enzymes which in turn may cause
depletion of the cofactors involved, leading to the alternations
observed in Hcy status [13].
In fact, an independent predictor of HHcy in patients trea-
ted with PHT or CBZ is the presence of a homozygous thermo-
labile genotype of 5,10 methyl tetrahydrofolate reductase
(MTHFR), suggesting a gene–drug interaction as a cause of
HHcy, this hypothesis is supported by Ono et al. [14]. Addi-
tionally, increased Hcy and low folate status may contributeto the development of AEDs related side effects, such as im-
paired cognitive function, and fetal malformation [15].
The aim of this study was to uncover the relationship be-
tween the levels of Hcy and the cofactors involved in its metab-
olism as folic acid and vitamin B12 and AEDs in epileptic
patients.
2. Subjects and methods
2.1. Subjects
This study was a cross-sectional study, conducted on 60 epilep-
tic children diagnosed with idiopathic epilepsy according to the
guidelines of The Classiﬁcations of the International League
Against Epilepsy (1998) [16], with age ranging from 5 to
15 years old. They were recruited from the Pediatric Neurol-
ogy outpatients’ clinic of Children’s Hospital, Ain Shams
University.
Patients were divided into two groups: Group (I), com-
prised 20 newly diagnosed epileptic children not receiving
anti-epileptic medication (non-AED users). Group (II), com-
prised 40 epileptic children on regular antiepileptic medication
for at least one year (AED users). Group II was further subdi-
vided into: Subgroup (A) which comprised 20 epileptic chil-
dren receiving monotherapy. Therapy consisted of either
valproic acid (VPA) or carbamazepine (CBZ). VPA group
comprised 12 children and CBZ group comprised 8 children.
Subgroup (B), receiving polytherapy treatment (combined
treatment with VPA and CBZ) comprised 20 patients. Serum
concentrations of both VPA and CBZ were maintained within
the therapeutic range throughout the study (71.4 ± 13.09 lg/ml
and 7 ± 1.9 lg/ml, respectively).
Thirty non-epileptic children of the same age and sex as pa-
tients served as controls. Children with diseases affecting the
serum level of Hcy as endocrinal, liver, kidney and cardiac dis-
eases, diabetes mellitus and nutritional deﬁciencies or those
receiving vitamin supply or folic acid antagonists as well as
the vegetarians were excluded from the study. Moreover, pa-
tients with uncontrolled seizures were excluded from the study
to limit the variables and to make sure not to change the dose
of AEDs throughout the study.
2.2. Methods
After obtaining the approval of the Ethics Committee at the
Pediatric Hospital, Ain Shams University, consents for partic-
ipating in the study were signed by the parents or caregivers.
Children were subjected to the following: Detailed history lay-
ing stress on age of onset of seizure, milestones of develop-
ment, symptoms of neurological deﬁcits as well as symptoms
suggestive of an underlying etiology (according to the commis-
sion on Epidemiology and Prognosis, International League
against Epilepsy, 1989) [16], type of seizure disorder (according
to the recommendations of the International League against
Epilepsy, 1981) [17] and duration of the disease. Care should
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months before the study, and we checked their dose, duration
of treatment, preparations and response to treatment. Com-
plete physical and neurological examinations were also done
for all patients.
2.3. Sampling
Estimation of serum levels of Hcy, folic acid and vitamin B12
were done using Chemiluminescent technique (Immulite 2000).
Patients must be in a fasting state [18]. Blood was drawn by
venipuncture in sterile plain vacutainer tubes; incubated in
water bath at 37 C for 15 min, centrifugated at 10,000 RPM
then serum was separated in sterile Epindorph tubes. To pre-
vent erroneous results due to the presence of ﬁbrin ensure that
complete clot formation has taken place prior to centrifugation
of samples. Some samples, particularly those from patients
receiving anticoagulant therapy, may require increased clotting
time.
2.4. Statistical methods
Statistical package for social science (SPSS) program version
9.0 was used for analysis of data. Data were summarized as
mean and SD. Non parametric test (Mann Whitney U) was
used for analysis of two quantitative data as data were not
symmetrically distributed. One way ANOVA was done for
analysis of more than two quantitative data followed by post
HOCC test for detection of signiﬁcance. Simple linear correla-
tion (Spearman’s correlation) was also done. ‘‘r’’ value was
considered weak if <0.25, mild if P0.25–<0.5, moderate if
P0.5–<0.75 and strong if P0.75.
3. Results
Regarding the epileptic patients included in the study their
mean age was 9.3 ± 3.5 years. Thirty (50%) were males and
30 (50%) were females. Generalized epilepsy was found in 44
(73.3%) and focal epilepsy in 16 (26.7%) of the studied pa-
tients. Out of these patients, 20 epileptic children were not
receiving anti-epileptic medication (non-AED users). Their
mean age was 7 ± 3.16 years, and 40 epileptic children were
on regular antiepileptic medication (AED users), their mean
age was 10.5 ± 3.16 years. They were further subdivided into:
20 epileptic children receiving monotherapy of mean age
10.3 ± 3.4 years, and the other 20 patients receiving poly-
therapy treatment of mean age 10.6 ± 2.9 years. They were
compared to 30 non-epileptic children of mean age
11.0 ± 2.4 years.Table 1 Comparison between mean serum levels of homocysteine a
non AED users) and controls.
Variables Epileptic patients
Mean ± SD
N= 60
Homocysteine (lmol/l) 5.9 ± 2.4
Folic acid (ng/ml) 7.7 ± 3.1
Vitamin B 12 (pg/ml) 495.7 ± 231.1
* P value is signiﬁcant <0.05.Our study showed that the mean serum levels of Hcy and
folic acid showed non signiﬁcant differences between epileptic
patients (both AED users and non AED users) and the con-
trols (p= 0.07, p= 0.6, respectively). However, the mean ser-
um level of vitamin B12 was signiﬁcantly higher in epileptic
patients compared to the controls (p= 0.03) (Table 1). The
mean serum levels of Hcy, folic acid and vitamin B12 showed
comparable results in non AED users, AED users and the con-
trols (Table 2).
Epileptic patients on polytherapy treatment showed higher
mean serum levels of Hcy and vitamin B12 and lower mean
serum levels of folic acid compared to those on monotherapy
treatment (Table 3). However, the mean serum levels of Hcy,
vitamin B12 and folic acid showed non signiﬁcant differences
between patients using VPA or CBZ (Table 4).
The mean serum levels of Hcy, vitamin B12 and folic acid
did not show signiﬁcant difference among epileptic patients
with different seizure types.
A signiﬁcant positive correlation was detected between the
duration of therapy and the serum Hcy levels (r= 0.4,
p= 0.02) (Fig. 1), however there was a signiﬁcant negative
correlation between duration of therapy and serum folic acid
levels (r= 0.5, p= 0.003) (Fig. 2).
A negative correlation was detected between the mean ser-
um levels of Hcy and folic acid in all epileptic patients as well
as in those receiving AEDs. (r= 0.6 and r= 0.5, respectively;
p= 0.0001 and p= 0.002, respectively) (Figs. 3 and 4).
4. Discussion
The mechanism of the association between homocysteine and
epilepsy is not fully understood, it is recommended that AEDs
increase serum Hcy by decreasing the blood folate levels, due
to antifolate properties, and depletion of other vitamins like
B2 and B6 [19,20].
Our study showed that Hcy and folic acid serum levels
showed non signiﬁcant differences between patients (both
AED users and non AED users) and controls and this is in
accordance with the study of Schwaninger et al. [21]. More-
over, when comparing serum levels of Hcy, folic acid and vita-
min B12 in patients receiving AEDs, non-AED users and
controls, they showed comparable results. These results are
in agreement with previous studies of Sener et al. [20] and
Kurul et al. [22].
Our ﬁnding of higher mean serum level of Hcy in patients
receiving polytherapy compared to those receiving mono-
therapy is partly supported by evidence from previous litera-
ture [13,14], and is further reinforced by the MTHFR 677TT
genotype; where among patients receiving multidrug therapy,nd its co-factors among epileptic patients (both AED users and
Controls
Mean ± SD
N= 30
P-value
5.5 ± 1.4 0.07
6.4 ± 2.9 0.6
443.9 ± 150.3 0.03*
Table 2 Comparison between levels of homocysteine and its co-factors among epileptic patients AED users, non AED users and
controls.
Variables Non-AED users
N= 20
AED users
N= 40
Controls
N= 30
P-value
Homocysteine (lmol/l) 5.8 ± 1.4 6.0 ± 2.7 5.5 ± 1.4 0.5
Folic acid (ng/ml) 7.3 ± 1.9 7.9 ± 3.5 6.4 ± 2.9 0.1
Vitamin B 12 (pg/ml) 433.5 ± 171.2 526.8 ± 252.1 443.9 ± 150.3 0.1
Table 3 Comparison between levels of homocysteine and its
co-factors among epileptic patients receiving polytherapy and
those receiving monotherapy.
Variables Monotherapy
Mean ± SD
N= 20
Polytherapy
Mean ± SD
N= 20
P-value
Homocysteine (lmol/l) 5.4 ± 1.6 6.7 ± 3.3 0.2
Folic acid (ng/ml) 8.2 ± 2.7 7.7 ± 4.2 0.7
Vitamin B 12 (pg/ml) 491.5 ± 299.9 562.0 ± 194.6 0.4
Table 4 Comparison between levels of homocysteine and its
co-factors among epileptic patients receiving VPA and those
receiving CBZ.
Variables CBZ
Mean ± SD
N= 8
VPA
Mean ± SD
N= 12
P-value
Homocysteine (lmol/l) 5.5 ± 1.9 5.4 ± 1.6 0.9
Folic acid (ng/ml) 6.4 ± 2.7 8.7 ± 2.6 0.09
Vitamin B 12 (pg/ml) 456.4 ± 252.5 503.2 ± 321.3 0.8
VPA: valproic acid, CBZ: carbamazepine.
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Figure 1 Positive correlation between mean serum levels of
homocysteine and duration of treatment of epileptic patients.
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Figure 3 Negative correlation between mean serum levels of
homocysteine and folic acid in epileptic patients (both AED users
and non AED users).
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Figure 4 Negative correlation between mean serum levels of
homocysteine and folic acid in anti-epileptic drug users.
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Figure 2 Negative correlation between mean serum levels of
folic acid and duration of treatment in epileptic patients.
278 O.N. Eldeen et al.HHcy in homozygotes for C677T occurred signiﬁcantly more
often than in heterozygotes or patients with no mutant enzyme
[14]. However, Hcy levels showed no signiﬁcant difference be-
tween patients who were receiving CBZ or VPA and this is in
agreement with the studies done by Apeland et al. [23] and
Vurucu et al. [24], yet this is in contrast to Gidal et al. [25] re-
sults, who reported a statistically signiﬁcant decline in plasma
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ous studies reported elevated Hcy levels with CBZ and VPA
use [26,19,5].
Antiepileptic drugs could be able to induce HHcy through
the following mechanisms: reinhibition in vitamin absorption,
Hcy metabolism dysfunction, accelerated vitamin metabolism,
and modulation of renal function [27].
Although our study showed that the serum Hcy levels be-
tween patients and controls were not signiﬁcantly different,
yet all cases and particularly patients on antiepileptic drugs
demonstrated higher levels of Hcy. This result is compatible
with literature ﬁndings [13,20,27]. However, data regarding
AEDs and their effect on Hcy metabolism have been contro-
versial [19]. It has been reported that Hcy levels of patients
receiving AEDs increased by 11.4–40% [5,13]. As we studied
both epileptic patients who were not receiving AEDs
(non-AED users) and controls, we observed that there were
no differences in Hcy levels between them, suggesting that,
the increase of Hcy levels may be due to AEDs use, rather than
being epileptic in origin.
Themean serum level of vitamin B12was signiﬁcantly higher
in patients compared to controls and non signiﬁcantly higher in
patients on polytherapy than those on monotherapy. This is in
agreement with the study done by Tamura et al. [4]. This could
be explained by the fact that prolonged drug treatmentmay pos-
sibly cause slightly impaired ability of the liver to store vitamin
B12, thus increasing the circulating vitamin B12 levels, which
served as a sensitive biochemical index of hepatic damage due
to anticonvulsants [21]. On the contrary, Karabiber et al. [5]
and Aslan et al. [28] detected low vitamin B 12 levels in patients;
yet, their data were not statistically signiﬁcant. It is worth noting
that in patients receiving monotherapy treatment the type of
AEDused (VPAorCBZ) did not alter the serum level of vitamin
B12. This is in accordance to the ﬁnding of Kurul et al. [22].
Our study showed that mean serum folic acid levels were
signiﬁcantly lower in patients on polytherapy than those on
monotherapy. This is in accordance with the studies of Ono
et al. [14] and Huemer et al. [13]. However, serum folic acid
showed comparable results in patients who were receiving
VPA and those receiving CBZ. This is in agreement with the
studies of Gidal et al. [25] and Geda et al. [29]. AEDs may
interfere with both absorption and metabolism of folate. It
has also been suggested that AED-mediated decrease in plas-
ma folate concentrations may in part represent a drug–gene
interaction [30,14]. It is worth noting that in the study done
in 2005 by Huemer et al. [11] intervention with folic acid re-
sulted in signiﬁcantly higher folate and lower tHcy concentra-
tions at weeks 6 and 12 compared with patients receiving
placebo [13].
Also, we found that the duration of therapy correlated sig-
niﬁcantly with elevated serum Hcy and low serum folic acid,
which is similar to previous results [21,11,12]. A negative corre-
lation was detected between mean serum levels of Hcy and folic
acid in all epileptic patients as well as in those receiving AEDs.
Based on the previous observations, we can speculate that
AEDs might upset the homeostatic balance of Hcy and its
cofactors and cause abnormalities of their serum levels.
Furthermore, the duration of AEDs is correlated signiﬁ-
cantly to the decrease of folic acid levels and to the increase
in Hcy levels. We suggest that the AEDs, rather than the dis-
ease, play a major role in the development of homocysteinemia
in epileptic patients. So, we recommend to routinely screenHcy and its cofactors levels in epileptic patients, and be treated
when their levels are found to be disturbed.Grants, sponsors and funding sources
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